tbuckley/cabot-search huggingface dataset:
Abstract P024: Administrative Billing Codes Accurately Identify Occurrence of Electrical Cardioversion and Ablation/Maze Procedures in Atrial Fibrillation Patients
Authors: Alexa N Ehlert, Susan R Heckbert, Kerri L Wiggins, Evan L Thacker
Journal: Circulation (2017)

Introduction: Administrative billing codes for electrical cardioversion and ablation/maze procedures may be useful for research on atrial fibrillation (AF) progression and treatment if the codes are sufficiently accurate relative to medical record documentation. Hypothesis: We hypothesized that administrative billing codes for electrical cardioversion and ablation/maze procedures would accurately identify the occurrence of those procedures. Methods: We studied adults ages 30-84 years who experienced new onset AF between 10/2001 and 12/2004, and were patients in Group Health, an integrated healthcare system in Washington state. Using medical record review as the gold standard, we assessed the accuracy of administrative billing codes for detecting the occurrence of electrical cardioversion and ablation/maze procedures. We calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for each billing code separately, and collectively for each procedure. Results: Of 1953 study participants with new onset AF, during a mean of 1.5 (SD 0.7) years of follow-up after AF onset, 470 (24%) experienced electrical cardioversion and 44 (2%) experienced ablation/maze procedures according to medical records. For cardioversion, CPT code 92960 performed better than ICD-9 codes 99.61 and 99.62, with higher sensitivity, PPV, and NPV, but slightly lower specificity. For ablation/maze, CPT code 93651 and ICD-9 code 37.34 performed identically, yielding higher sensitivity and PPV than ICD-9 code 37.33. For cardioversion and ablation/maze procedures, combining three codes improved sensitivity and NPV while maintaining high specificity and PPV relative to individual codes. (See Table.) Conclusions: Administrative billing data accurately identify electrical cardioversion and ablation/maze procedures, and can be used in place of medical record review. Our findings apply to integrated health systems or other settings where administrative billing databases are available.
Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer—Reply
Authors: Andrew J. Armstrong, Orjan Nordle, Michael Morris
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Regulator of telomere length 1 (<i>RTEL1</i>) mutations are associated with heterogeneous pulmonary and extra-pulmonary phenotypes
Authors: Raphael Borie, Diane Bouvry, Vincent Cottin, Clement Gauvain, Aurélie Cazes, Marie-Pierre Debray, Jacques Cadranel, Philippe Dieude, Tristan Degot, Stephane Dominique, Anne Sophie Gamez, Madeleine Jaillet, Pierre-Antoine Juge, Arturo Londono-Vallejo, Arnaud Mailleux, Hervé Mal, Catherine Boileau, Christelle Menard, Hilario Nunes, Gregoire Prevot, Sebastien Quetant, Patrick Revy, Julie Traclet, Lidwine Wemeau-Stervinou, Marie Wislez, Caroline Kannengiesser, Bruno Crestani
Journal: European Respiratory Journal (2018)

Regulator of telomere length 1 ( RTEL1 ) mutations have been evidenced in 5–9% of familial pulmonary fibrosis; however, the phenotype of patients with interstitial lung disease (ILD) and RTEL1 mutations is poorly understood. Whole exome sequencing was performed in 252 probands with ILD and we included all patients with ILD and RTEL1 mutation. RTEL1 expression was evaluated by immunochemistry in the lungs of controls, as well as in RTEL1 and telomerase reverse transcriptase ( TERT ) mutation carriers. We identified 35 subjects from 17 families. Median age at diagnosis of ILD was 53.1 years (range 28.0–80.6). The most frequent pulmonary diagnoses were idiopathic pulmonary fibrosis (n=20, 57%), secondary ILD (n=7, 20%) and unclassifiable fibrosis or interstitial pneumonia with autoimmune features (n=7, 20%). The median transplant-free and overall survival periods were 39.2 months and 45.3 months, respectively. Forced vital capacity at diagnosis was the only factor associated with decreased transplant-free survival. Extra-pulmonary manifestations were less frequent as compared to other telomere-related gene mutation carriers. A systematic analysis of the literature identified 110 patients with ILD and RTEL1 mutations (including this series) and confirmed the heterogeneity of the pulmonary phenotype, the prevalence of non-idiopathic diseases and the low prevalence of extra-pulmonary manifestations. Immunohistochemistry showed that RTEL1 was expressed by bronchial and alveolar epithelial cells, as well as by alveolar macrophages and lymphocytes, but not by fibroblasts.
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Authors: George Fromm, Suresh de Silva, Kellsey Johannes, Arpita Patel, Josiah C. Hornblower, Taylor H. Schreiber
Journal: Journal for ImmunoTherapy of Cancer (2018)

Simultaneous blockade of immune checkpoint molecules and co-stimulation of the TNF receptor superfamily (TNFRSF) is predicted to improve overall survival in human cancer.TNFRSF co-stimulation depends upon coordinated antigen recognition through the T cell receptor followed by homotrimerization of the TNFRSF, and is most effective when these functions occur simultaneously.To address this mechanism, we developed a two-sided human fusion protein incorporating the extracellular domains (ECD) of PD-1 and OX40L, adjoined by a central Fc domain, termed PD1-Fc-OX40L.The PD-1 end of the fusion protein binds PD-L1 and PD-L2 with affinities of 2.08 and 1.76 nM, respectively, and the OX40L end binds OX40 with an affinity of 246 pM.High binding affinity on both sides of the construct translated to potent stimulation of OX40 signaling and PD1:PD-L1/L2 blockade, in multiple in vitro assays, including improved potency as compared to pembrolizumab, nivolumab, tavolixizumab and combinations of those antibodies.Furthermore, when activated human T cells were co-cultured with PD-L1 positive human tumor cells, PD1-Fc-OX40L was observed to concentrate to the immune synapse, which enhanced proliferation of T cells and production of IL-2, IFNγ and TNFα, and led to efficient killing of tumor cells.The therapeutic activity of PD1-Fc-OX40L in established murine tumors was significantly superior to either PD1 blocking, OX40 agonist, or combination antibody therapy; and required CD4+ T cells for maximum response.Importantly, all agonist functions of PD1-Fc-OX40L are independent of Fc receptor cross-linking.Collectively, these data demonstrate a highly potent fusion protein that is part of a platform, capable of providing checkpoint blockade and TNFRSF costimulation in a single molecule, which uniquely localizes TNFRSF costimulation to checkpoint ligand positive tumor cells.
Abstract 16008: An Association Between Short Telomere Length and Major Cardiovascular Events is Influenced by the Proximity of Telomere Measurement to Event Occurrence
Authors: John F Carlquist, Stacey Knight, Richard Cawthon, Benjamin D Horne, Joseph B Muhlestein, Jeffrey L Anderson
Journal: Circulation (2016)

Background: Short telomere length (TL) is associated with cardiovascular (CV) events. However, disagreement exists as to the physiological association between TL and CV events. Short TL may indicat...
Imaging and Treatment of Post–90Y Radioembolization Radiation Dermatitis
Authors: Hian Liang Huang, Nanda Venkatanarasimha, Chung Yip Chan
Journal: Clinical Nuclear Medicine (2018)

Y microspheres have been widely used for treatment of liver-dominant malignancies. There have been a few case reports of radiation dermatitis post-inadvertent falciform artery Y radioembolization and a few retrospective studies with prophylactic coiling or use of ice packs prior to radioembolization. Our patient had inadvertent falciform artery radioembolization, which was not predicted on pretherapy angiography or Tc-macroaggregated albumin SPECT/CT but was localized on posttherapy Y PET/CT and treated with topical betamethasone valerate 0.1% BD and ice packing immediately postprocedure. He subsequently developed a small area of periumbilical radiation dermatitis, which resolved after 4 weeks.
Persistent Reduction of Mucin Production after Bronchial Thermoplasty in Severe Asthma
Authors: Ikhlass Haj Salem, Delphine Gras, Philippe Joubert, Louis-Philippe Boulet, Noel Lampron, Simon Martel, Krystelle Godbout, Pascal Chanez, Michel Laviolette, Jamila Chakir
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience
Authors: Issa F. Khouri, Denái R. Milton, Celina Ledesma, William D Erwin, Elias J. Jabbour, Gheath Alatrash, Paolo Anderlini, Qaiser Bashir, Stefan O. Ciurea, Jin S Im, David Marin, Rohtesh S. Mehta, Jeffrey J. Molldrem, Amanda L. Olson, Betul Oran, Uday Popat, Muzaffar H. Qazilbash, Gabriela Rondon, Richard E Champlin, L. Jeffrey Medeiros, Alison Gulbis
Journal: Blood (2018)
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Authors: J. Zugazagoitia, I. Ramos, J.M. Trigo, M. Palka, A. Gómez-Rueda, E. Jantus-Lewintre, C. Camps, D. Isla, P. Iranzo, S. Ponce-Aix, R. García-Campelo, M. Provencio, F. Franco, R. Bernabé, O. Juan-Vidal, E. Felip, J. de Castro, J.M. Sanchez-Torres, I. Faul, R.B. Lanman, P. Garrido, L. Paz-Ares
Journal: Annals of Oncology (2018)

BackgroundApproximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. We have analyzed the clinical utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) in patients with inadequate tumor samples for tissue genotyping.Patients and methodsWe conducted the study in a multi-institutional prospective cohort of clinically unselected patients with advanced-stage lung adenocarcinomas with insufficient tissue for EGFR, ALK or ROS1 genotyping across 12 Spanish institutions (n = 93). ctDNA NGS was carried out by Guardant Health (Guardant360, Redwood City, CA), using a hybrid-capture-based 73-gene panel. Variants were deemed actionable if they were part of the OncoKB precision oncology knowledge database and classified in four levels of actionability based on their clinical or preclinical evidence for drug response.ResultsEighty-three out of 93 patients (89%) had detectable levels of ctDNA. Potentially actionable level 1–4 genomic alterations were detected in 53 cases (57%), of which 13 (14%) had level 1–2A alterations (Food and Drug Administration-approved and standard-care biomarkers according to lung cancer guidelines). Frequencies of each genomic alteration in ctDNA were consistent with those observed in unselected pulmonary adenocarcinomas. The majority of the patients (62%), particularly those with actionable alterations (87%), had more than one pathogenic variant in ctDNA. The median turnaround time to genomic results was 13 days. Twelve patients (13%) received genotype-matched therapies based on ctDNA results, deriving the expected clinical benefit. Patients with co-occurring pathogenic alterations had a significantly shorter median overall survival as compared with patients without co-occurring pathogenic alteration (multivariate hazard ratio = 5.35, P = 0.01).ConclusionDigital NGS of ctDNA in lung cancers with insufficient tumor samples for tissue sequencing detects actionable variants that frequently co-occur with other potentially clinically relevant genomic alterations, allowing timely initiation of genotype-matched therapies.
Abstract P190: Developing a Reproductive Risk Prediction Model for Coronary Heart Disease in Women: The Women’s Health Initiative Observational Study
Authors: Nisha Parikh, Rebecca J Rodabough, Jeffrey S Berger, Charles Eaton, Candyce H Kroenke, Erin LeBlanc, Cora E Lewis, Eric B Loucks, Donna Parker, Eileen Rillamas-Sun, Kelli K Ryckman, Molly E Waring, Robert S Schenken, Matthew A Allison, Barbara V Howard
Journal: Circulation (2013)

Introduction: The 2011 AHA prevention guidelines recommend taking a pregnancy history in women for the aim of CHD risk stratification. Thus, we developed a reproductive history risk model for coronary heart disease (CHD) in women as the basis of a reproductive risk score. Methods: Data from 68,280 women in the Women’s Health Initiative Observational Study (WHI-OS) with ≥ one pregnancy and non-missing reproductive data, were used to construct a multivariable Cox proportional hazards model for CHD (MI, CHD death, revascularization) prediction. Follow up time began at enrollment and went until CHD event, loss to follow-up, death or censoring on September 30, 2010 (mean (SD) follow up=11.2 (3.2) years). An age-adjusted model was developed including candidate reproductive factors: age at menarche, menstrual regularity, number of live births, age at first birth, # of stillbirths, # of miscarriages, # of tubal pregnancies, subfertility (trying to conceive unsuccessfully for 1 year), subfertility cause, and breas...
Abstract 10134: Potassium Cardioplegia During CPR for Porcine VF Arrest: A Blinded Randomized Controlled Trial
Authors: Keith A Marill, David D Salcido, Matthew L Sundermann, Allison C Koller, James J Menegazzi
Journal: Circulation (2015)

Introduction: Potassium cardioplegia-induced transient asystole may conserve myocardial energy and improve outcome in ventricular fibrillation (VF) cardiac arrest. Hypothesis: We hypothesized potassium infusion during VF arrest would lead to an increase in intra-arrest amplitude spectrum area (AMSA) prior to defibrillation, and improved hemodynamic parameters in those animals that attained return of spontaneous circulation (ROSC). Methods: Twelve swine were randomized to KCl or placebo in a randomized controlled trial, and 10 were included in an amended protocol. After initiation of monitoring, induction of anesthesia, and instrumentation of the aorta and right atrium, VF was electrically induced. After 4 minutes, 1.5 meq/kg KCl or placebo was infused in blinded fashion in a peripheral ear vein and mechanical chest compressions and ventilations were begun. Initial defibrillation was performed 10 minutes post VF induction, as appropriate. Animals without ROSC received continued resuscitation per Advanced Cardiac Life Support(ACLS) guidelines for 10 more minutes. Animals that achieved ROSC were monitored for 30 more minutes. The primary outcome, change in AMSA from just before study drug infusion to 5 minutes post infusion, was compared using nonparametric statistics. Results: Six animals were randomized to KCl and 4 to Placebo. KCl infusion induced approximately 1 minute of transient asystole at the dosage used. The mean change in normalized AMSA was -0.24 in the KCl and 0.21 in the Placebo group, with a median difference of -0.50 (95%CI -0.79 to -0.09), p=0.038, favoring Placebo. Five of 6 (83%) animals in the KCl group and 2 of 4 (50%) in the Placebo group developed an organized, though not necessarily, perfusing rhythm with the difference in proportion 33% (95% CI -33 to 86). One of 6 (17%) animals in the KCl and 2 of 4 (50%) in the Placebo group achieved ROSC with the difference in proportion -33% (95%CI -93 to 33). Hemodynamics were not quantitatively compared post ROSC due to limited survivors. One animal in each group required norepinephrine infusion. Conclusions: Potassium as a single agent did not benefit AMSA or ROSC in this porcine model of VF arrest.
Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles
Authors: Mayte Suárez-Fariñas, Maria Suprun, Helena L. Chang, Gustavo Gimenez, Galina Grishina, Robert Getts, Kari Nadeau, Robert A. Wood, Hugh A. Sampson
Journal: Journal of Allergy and Clinical Immunology (2018)
Abstract P151: Vitamin K Intake and All-cause and Cause Specific Mortality
Authors: Sabine R Zwakenberg, Nicolette den Braver, Anouk I Engelen, Edith J Feskens, Cees Vermeer, Jolanda M Boer, W M Monique Verschuren, Yvonne T van der Schouw, Joline W Beulens
Journal: Circulation (2016)

Background: Vitamin K has been associated with various health outcomes, including non-fatal cardiovascular diseases and cancer. However, little is known about the association between vitamin K intake and all-cause and cause specific mortality. Objective: To investigate the association between vitamin K intake and all-cause and cause specific mortality. Methods: This prospective cohort study included 33,289 participants, aged 21-70 years from the EPIC-NL cohort. Participants were recruited between 1993 and 1997 and the follow-up is complete until December 2012. Dietary intake was assessed at baseline with a 178-item validated food frequency questionnaire and intakes of total vitamin K intake and its sub forms, phylloquinone, menaquinones (MK), short-chain menaquinones (SMK) and long-chain menaquinones (LMK) were calculated. Information on vital status and causes of death was obtained through linkage to several registries. The association between the different forms of vitamin K intake and mortality was assessed with Cox proportional hazard regression, adjusted for risk factors for chronic diseases (gender, age, BMI, physical activity, smoking status, education level) and nutrient intake. Results: During a median follow-up of 16.8 years, 2,863 deaths occurred, including 625 from CVD (256 CHD specific), 1,346 from cancer and 894 from other causes. After multivariable adjustment, vitamin K intake was not associated with all-cause mortality with hazard ratios for the upper vs. the lowest quartile of phylloquinone and menaquinone intake of 1.04 (0.93-1.17) and 0.94 (0.82-1.07) respectively. Phylloquinone intake nor menaquinone intake was associated with risk of CVD mortality. Higher intake of LMK was borderline significantly associated (p trend = 0.06) with lower CHD mortality with a HR per 10 μg of 0.87 (0.75-1.01). None of the forms of vitamin K intake were associated with cancer mortality or mortality from other causes. Conclusions: Vitamin K intake was not associated with all-cause mortality, cancer mortality and mortality from other causes. A higher intake of LMK tended to be associated with a lower risk of CHD mortality.
Total Aqueous Synthesis of Au@Cu<sub>2−</sub><i><sub>x</sub></i>S Core–Shell Nanoparticles for In Vitro and In Vivo SERS/PA Imaging‐Guided Photothermal Cancer Therapy
Authors: Qian Lv, Huan Min, Dong‐Ban Duan, Wei Fang, Gui‐Ming Pan, Ai‐Guo Shen, Qu‐Quan Wang, Guangjun Nie, Ji‐Ming Hu
Journal: Advanced Healthcare Materials (2018)

Abstract Both accurate tumor navigation and nanostructures with high photothermal (PT) conversion efficiency are important but remain challenging to achieve in current biomedical applications. This study reports an anion exchange‐based facile and green approach for synthesizing Au@Cu 2− x S core–shell nanoparticles (NPs) in an aqueous system. In addition to the PT effect of the suggested NPs, the surface‐enhanced Raman scattering (SERS) is also significantly improved due to the tailored localized surface plasmon resonance coupling between the Au metal core and the Cu 2− x S semiconductor shell. Using an epitaxial strategy, Au@Cu 2 O NPs are first obtained by the in situ reduction of cupric hydroxide on a cresyl violet acetate‐coated Au core; then, Au@Cu 2− x S NPs are obtained via anion exchange between the S 2− and Cu 2 O shell. Both the Cu/S atomic ratio and the Cu 2− x S shell thickness can be adjusted conveniently. Hence, the ideal integration of the plasmonic Au core and Cu 2− x S shell into a single unit is conducive not only to highly efficient PT conversion but also to the construction of a SERS‐based navigator. This new type of SERS‐guided NP, with enhanced photoacoustic signals, is an important candidate for both accurate tumor navigation and nondestructive PT treatment guided in vivo by two modes of optical imaging.
Anti-Ro52 antibody acts on the S5-pore linker of hERG to chronically reduce channel expression
Authors: John Szendrey, Shawn M Lamothe, Stephanie Vanner, Jun Guo, Tonghua Yang, Wentao Li, Jordan Davis, Mala Joneja, Adrian Baranchuk, Shetuan Zhang
Journal: Cardiovascular Research (2018)

The human ether-a-go-go-related gene (hERG) encodes the rapidly activating delayed rectifier potassium channel (IKr). Malfunction of hERG/IKr is the primary cause of acquired long QT syndrome (LQTS), an electrical disorder of the heart that can cause arrhythmias and sudden death. Patients with autoimmune diseases display a high incidence of LQTS. While dysfunction of hERG channels induced by autoantibodies such as anti-Ro52 may play a role in this pathology, the underlying mechanisms are not well understood. Here, we investigated the acute and chronic effects of anti-Ro52 antibody on hERG channels stably expressed in human embryonic kidney (hERG-HEK) 293 cells as well as IKr in neonatal rat ventricular myocytes. Using whole-cell patch clamp, western blot analyses, and immunocytochemistry, we found that a 12-h treatment of hERG-HEK cells with patients' sera containing anti-Ro52 autoantibody decreased the hERG current (IhERG) by 32% compared to cells treated with autoantibody-negative patients' sera. Commercial anti-Ro52 antibody at 100 µg/mL did not acutely block IhERG. Instead, a 12-h treatment with anti-Ro52 antibody at a concentration of 4 µg/mL significantly reduced mature hERG protein expression and IhERG. Specifically, anti-Ro52 antibody did not acutely block hERG current but chronically facilitated hERG endocytic degradation. The extracellular S5-pore linker of hERG, which forms the turret of the channel on the outside of the cell, is the target region for anti-Ro52-mediated hERG reduction since its replacement with the analogous region of EAG abolished the anti-Ro52 effect. In neonatal rat ventricular myocytes, 100 µg/mL anti-Ro52 antibody did not acutely block IKr, but a 12-h treatment of cells with 4 µg/mL anti-Ro52 antibody selectively reduced IKr and prolonged the action potential duration. Our results indicate that anti-Ro52 antibody acts on the hERG S5-pore linker to chronically decrease hERG expression and current. These findings provide novel insights into hERG regulation and anti-Ro52 antibody-associated LQTS.
Portal vein embolization does not affect the long-term survival and risk of cancer recurrence among colorectal liver metastases patients: A prospective cohort study
Authors: Yves Collin, Alex Paré, Assia Belblidia, Richard Létourneau, Marylène Plasse, Michel Dagenais, Simon Turcotte, Guillaume Martel, André Roy, Real Lapointe, Frank Vandenbroucke-Menu
Journal: International Journal of Surgery (2018)